Compare Globus Medical Inc. Class A Common Stock (GMED) vs Nextpower Inc. Common Stock (NXT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs Nextpower Inc. Common Stock — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.85 (market cap $10.25B), while Nextpower Inc. Common Stock trades at $81 (market cap $12.53B). The key difference: Nextpower Inc. Common Stock is the larger of the two by market cap, and Globus Medical Inc. Class A Common Stock is trading nearer its 52-week high, Nextpower Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Nextpower Inc. Common Stock for 0 Days on average.
| GMED | NXT | |
|---|---|---|
Market Cap | $10.25B | $12.53B |
Volume | 1,059,528 | 3,195,746 |
Sector | Health | Energy |
52-Week High | $96.82 | $156.40 |
52-Week Low | $58.33 | $77.93 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $9.76B | $11.98B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
NXT trades at $88.77, up 4.61% today, with strong analyst support (86% buy ratings) and a $144.67 consensus price target suggesting 63% upside. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results expected November 16. Revenue grew from $3.0B in 2025 to $3.6B in 2026, while maintaining robust profitability with 16.36% net margins and 27.22% ROE.
Positive outlook driven by $5.5B+ backlog and raised 2027 guidance, though rising platform investment costs and solar sector volatility present risks. Technical levels show support at $86 with resistance at $91, while valuation multiples (P/E 22.94, P/S 3.76) appear reasonable given growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About Nextpower Inc. Common Stock
Nextpower Inc., formerly known as Nextracker, is a solar energy technology company that designs tracking systems, structural foundations, and electrical balance-of-system equipment for utility-scale solar power plants. The company also develops software for solar yield management and is expanding into utility-scale power conversion systems.
Read more on NXT →
